Idera Pharmaceuticals Acquires Aceragen

Idera Pharmaceuticals

EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced it recently completed the acquisition of Aceragen, Inc., a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments.

The combined cash of the two companies is expected to provide a runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones.

The Company stated that it estimates an annual peak sales potential of $650 million from the three current lead programs.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.

READ:  Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China